Jennifer Yeong-shin Sheng MD (She/Her)

Breast Cancer

Medical Oncologist

5255 Loughboro Road NorthwestBuilding BWashington, DC 20016
Phone+1 202-660-6500
Fax+1 202-660-6501

Dr. Sheng is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sheng's full profile Already have an account?

Summary

Dr. Sheng is a Breast Medical Oncologist and Assistant Professor at Johns Hopkins School of Medicine. Her research focuses on cardio metabolic health and lifestyle interventions. She has received the NCCN Young Investigator Award, Inaugural Evelyn Lauder YIA & ACS Clinician Scientist Development Grant.

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2016 - 2019
Temple University HospitalResidency, Internal Medicine, 2013 - 2016
Rutgers New Jersey Medical SchoolClass of 2013

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

VA State Medical License 2023 - 2028
MD State Medical License 2016 - 2027
DC State Medical License 2022 - 2026
PA State Medical License 2013 - 2022
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Clinician Scientist Development Grant American Cancer Society, 2026
NCCN Young Investigator Award National Comprehensive Cancer Network, 2020
Inaugural Evelyn Lauder Young Investigator Award Breast Cancer Research Foundation and Conquer Cancer Foundation, 2019

Clinical Trials

Adaptive Nutrition and Exercise Weight Loss (A-NEW) Study Start of enrollment: 2021 Feb 08
COMPLETED
PHASE2
Gut Microbiome, Adverse Effects, and Markers Through MEtabolic Reprogramming Start of enrollment: 2024 Aug 08
RECRUITING
NA
Cardiometabolic Screening Program Start of enrollment: 2022 Jun 03
RECRUITING
NA

Publications & Presentations

PubMed

4 citations
Healthcare provider perspectives on a clinical decision tool to support individualized exercise prescriptions and discussions for breast cancer survivors.
Jinani Jayasekera, Oliver W A Wilson, Kaitlyn M Wojcik, Eleanor M Kerr, Rachelle Brick
Journal of Cancer Survivorship. 2026-08-01
1 citations
The Impact of Baseline Sleep as a Potential Moderator of Weight Loss Intervention in Breast Cancer Survivors: Results From the POWER-Remote Trial.
Jennifer Y Sheng, Ruizhe Chen, Gary L Rosner, Claire F Snyder, Lawrence J Appel
Obesity. 2026-02-01
1 citations
Combined technology-enhanced home exercise and acupressure (TEHEplus) program on symptoms among cancer patients receiving immunotherapy: a feasibility study.
Nada Lukkahatai, Chitchanok Benjasirisan, Aomei Shen, Junxin Li, Sarah Allgood
BMC Cancer. 2025-10-01

Press Mentions

Unique Considerations for Patients with Early-Onset Breast CancerDecember 18th, 2024
Behind the Study: Weight Loss Strategies for Breast Cancer SurvivorsMarch 3rd, 2022
LG Chem Life Sciences and TransThera Biosciences Announce FDA Clearance of IND for TT-01025, a SSAO/VAP-1 InhibitorDecember 1st, 2020